Greetings and welcome to episode #13 of the Alzheimer’s Solution Revolution podcast!

Today I am very much looking forward to pod-talking about one of the most important components associated with accelerated aging processes, and in the risk for Alzheimer’s disease— the decline and inhibition of critical energy metabolism systems of the body and brain.

Many studies have shown that alterations in mitochondrial energy metabolism, or bioenergetics, have been linked to numerous disorders that disrupt normal metabolism, and it is a factor in brain aging and a number of neurodegenerative diseases such as Alzheimer’s.

Aging is associated with progressive mitochondrial dysfunction and deficits of ATP, which underlies “The Mitochondrial Basis of Aging” hypothesis.

Now the role of mitochondrial function in biological aging and brain health is indeed vast, so I’ll keep the focus in this podcast on two key components of brain energy metabolism, or neuroenergetics—dysfunctional glucose metabolism and insulin resistance, and a few key risk factors that can increase the risk for both.

Now, in brain energy metabolism, glucose is the most readily available fuel for youthful energy metabolism is glucose.

However, in the aging brain there is often a progressive decline in glucose utilization and brain energy metabolism, or glucose hypometabolism, which is a known risk factor for cognitive decline and impairment.

“The decline in brain energy metabolism distinguished by glucose hypometabolism and mitochondrial dysfunction are a significant set of related risk factors that are now viewed as early metabolic antecedents that set the stage for the development of late-onset Alzheimer’s disease (LOAD).”

And, “Without the capacity to burn fuel for energy metabolism, an energy crisis is set forth in the neuron that gradually erodes our cognitive performance and sets the stage for the onset of late-onset Alzheimer’s disease (LOAD).”
Many studies have demonstrated that impairments in cerebral glucose metabolism and glucose hypometabolism to be a specific correlate to the cognitive dysfunction in the early stages of mild cognitive impairment (MCI), and to the eventual development of LOAD.

Aditionally, such studies have surmised that evaluations that show a reduction in cerebral glucose utilization can accurately predict future cognitive decline in normal individuals as well as the conversion to mild cognitive impairment.

Now, a set of risk factors associated with aging are particularly notable in the risk for impaired glucose metabolism in the brain and the risk for cognitive impairment and dementia.

• Atherosclerosis,
• Brain insulin resistance,
• The ApoE4 genetic variant, and
• Estrogen deficits in women

Lastly, I want to emphasize the role oxidative stress (OS) with regard to mitochondrial function.

In the body and brain, OS is the result of environmental exposures and endogenous production of free radicals from mitochondrial energy metabolism.

Oxygen is required for mitochondrial ATP production and it is a major source of reactive chemicals that are potentially very damaging molecules.

And, an environment of OS is created when there is not an adequate reserve or supply of antioxidants such as glutathione that neutralize damaging oxygen based free radicals that are termed—reactive oxygen species (ROS).

An excess of ROS and the induction of oxidative stress damages cells and their DNA and can lead to cell death.

Case in point, in brain glucose hypometabolism and the mitochondrial dysfunction associated with it, excessive oxygen radicals are generated which overwhelm the normal antioxidant resources of the mitochondria and brain cells.

Not to be overlooked in all of this is the fact that there are a host of laboratory-based biomarker assessments that are easily accessed, and those assessments can guide an early intervention and risk reduction strategy.

Please listen in to the full story on the role of “Glucose Hypometabolism, Impairments in Mitochondrial Function, and Oxidative Stress as Major Risk Factors for Alzheimer’s Disease”.

• The brain, despite comprising only ~2% of total body weight, consumes approximately 20–25% of resting metabolic energy expenditure, making it exceptionally vulnerable to disruptions in mitochondrial energy metabolism (ATP production). When neuronal energy demands are no longer adequately met, a progressive bioenergetic crisis emerges that compromises synaptic function, neuronal survival, and long-term cognitive resilience.

• Glucose hypometabolism which is the declining ability of the brain to efficiently utilize glucose as energy fuel substrate, is now recognized as one of the earliest metabolic abnormalities associated with late-onset Alzheimer’s disease. Reductions in cerebral glucose utilization can be detected decades before clinical symptoms appear and are strongly correlated with future cognitive decline, brain atrophy, and progression toward dementia.

• Mitochondrial dysfunction in aging is driven by cumulative mitochondrial DNA damage, impaired mitophagy (clearance of dysfunctional mitochondria), and reduced mitochondrial biogenesis (generation of new mitochondria, both of which are essential processes for maintaining healthy cellular energy systems. The progressive breakdown of these mitochondrial quality-control mechanisms (mitophagy) and biogenesis underlies declining ATP production and increased susceptibility to neurodegenerative disease.

• Maternally inherited mitochondrial abnormalities may contribute to Alzheimer’s susceptibility through inherited tendencies toward glucose hypometabolism and elevated oxidative stress. Research demonstrating metabolic deficits in adult offspring of mothers with a history of Alzheimer’s disease highlights the importance of mitochondrial inheritance patterns in neurodegenerative risk.

• The ApoE4 genetic variant is associated with structural and functional vulnerabilities that include impaired cerebral glucose metabolism, mitochondrial dysfunction, and increased oxidative stress, which largely predisposes ApoE4 carriers to a chronic hypometabolic brain state that may accelerate neurodegenerative processes during aging.

• The “type 3 diabetes” hypothesis conceptualizes Alzheimer’s disease as a form of brain-specific insulin resistance characterized by impaired glucose metabolism and dysfunctional insulin signaling which is similar to type 2 diabetes. These shared metabolic abnormalities help explain the strong relationship between type 2 diabetes, metabolic syndrome, type 3 diabetes, and the elevated Alzheimer’s risk later in life.

• Beta-amyloid protein aggregates localize at neuronal synapses where they disrupt insulin receptor signaling and impair the synaptic pathways involved in memory formation and learning. This progressive loss of insulin sensitivity contributes directly to impaired glucose uptake, ATP deficiency, synaptic dysfunction, and the broader neuroenergetic collapse associated with Alzheimer’s pathology.

• Atherosclerosis, vascular disease, hypertension, obesity, and type 2 diabetes collectively impair cerebral blood flow and reduce delivery of oxygen and nutrients required for mitochondrial ATP generation. These vascular-metabolic disturbances further intensify beta-amyloid and tau aggregation, accelerating the development of Alzheimer’s-related neurodegeneration.

• Estrogen functions as a major regulator of brain energy metabolism in women, and its decline during menopause may significantly increase susceptibility to glucose hypometabolism and neurodegenerative disease. This metabolic vulnerability is believed to contribute to the disproportionately higher prevalence of Alzheimer’s disease among women.

• Research examining menopausal hormone replacement therapy (HRT) suggests that early intervention during the menopausal transition may provide neuroprotective benefits by supporting cerebral metabolism and mitochondrial function. Studies also indicate that natural HRT formulations may offer greater protective effects than synthetic alternatives, while delayed initiation may diminish potential benefits or increase risk.

• Ketone bodies (molecules derived from fatty acids) provide an alternative mitochondrial fuel source capable of bypassing impaired glucose metabolism in the aging brain. Ketogenic dietary therapies, intermittent fasting, caloric restriction, and medium-chain triglyceride supplementation have emerged as metabolic interventions that may help sustain neuronal bioenergetics and slow progression during the early stages of Alzheimer’s disease.

• Oxidative stress represents both a consequence and amplifier of mitochondrial dysfunction. Excess reactive oxygen species generated during impaired mitochondrial metabolism overwhelm antioxidant defenses such as glutathione, leading to mitochondrial DNA damage, neuroinflammation, cellular degeneration, and progressive disruption of neuronal integrity.

• Chronic inflammation and oxidative stress function as highly interconnected biological processes that reinforce mitochondrial dysfunction and neurodegenerative progression. The oxidative stress hypothesis and mitochondrial cascade hypothesis both propose that cumulative mitochondrial damage and impaired antioxidant compensation mechanisms are central drivers of brain aging and late-onset Alzheimer’s disease.

• Many of the metabolic abnormalities associated with Alzheimer’s risk, including insulin resistance, glucose dysmetabolism, vascular dysfunction, oxidative stress, and chronic inflammation, can be evaluated through accessible laboratory biomarkers and targeted risk assessments. Because these mechanisms are potentially modifiable, early metabolic intervention may represent one of the most important strategies for reducing long-term neurodegenerative risk.

Epidsode 13

Timestamp Highlights

Please listen in!

Ralph Sanchez, MTCM, CNS, D.Hom

BrainDefend®

www.TheAlzheimersSolution.com

www.facebook.com/TheAlzheimersSolution

www.linkedin.com/in/ralph-sanchez

www.instagram.com/alzheimers_solution